Hyperoxaluria Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments
Hyperoxaluria Pipeline Analysis report covers 6 drugs currently in different phases of development. Hyperoxaluria is a disease which occurs when there is excessive oxalate present in the urine. Oxalate is naturally present in the body and in certain foods but too much oxalate may lead to complications such as kidney stones. The condition may be inherited or acquired by eating too-much of oxalate rich diet. The disease is classified as Primary Hyperoxaluria (PH) or Secondary Hyperoxaluria (SH). Symptoms of hyperoxaluria are back pain, persistent pain below the ribs, hematuria, frequent urination, pain while urinating and fever. PH is a rare autosomal recessive disorder while SH is either by a defect secretion of oxalate to the intestine or by a defect absorption of oxalate from the intestine.
The report provides Hyperoxaluria treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Allena Pharmaceuticals, Inc., Captozyme and Intellia Therapeutics, Inc. among others.
Scope:
By Company:
By Phase
By Molecule Type
By Region
By Route of Administration
Hyperoxaluria Pipeline Analysis report covers 6 drugs currently in different phases of development. Hyperoxaluria is a disease which occurs when there is excessive oxalate present in the urine. Oxalate is naturally present in the body and in certain foods but too much oxalate may lead to complications such as kidney stones. The condition may be inherited or acquired by eating too-much of oxalate rich diet. The disease is classified as Primary Hyperoxaluria (PH) or Secondary Hyperoxaluria (SH). Symptoms of hyperoxaluria are back pain, persistent pain below the ribs, hematuria, frequent urination, pain while urinating and fever. PH is a rare autosomal recessive disorder while SH is either by a defect secretion of oxalate to the intestine or by a defect absorption of oxalate from the intestine.
The report provides Hyperoxaluria treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Allena Pharmaceuticals, Inc., Captozyme and Intellia Therapeutics, Inc. among others.
Scope:
By Company:
By Phase
- NDA filed
- Phase III
- Phase II
- Phase I
- Pre-clinical
- Discovery
By Molecule Type
- Small molecules
- Biologics
- Peptides or Small proteins
By Region
- North America
- South America
- Europe
- Middle East and Africa
- Asia Pacific
By Route of Administration
- IV
- IM
- S/C
- Oral
Table of Contents
1. Introduction1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profile
- Drug Name
- Generic Name
- Synonyms
- Company
- Collaborator
- Route of administration
- Target
- Mechanism of Action
- Technology
- Molecule type
- CAS Number
- Weight
- Chemical Formula
- IUPAC name
- ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Allena Pharmaceuticals, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Alnylam Pharmaceuticals, Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Captozyme
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Dicerna Pharmaceuticals, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Intellia Therapeutics, Inc.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. OxThera
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
List of Tables
List of Figures
Companies Mentioned
- Allena Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Captozyme
- Dicerna Pharmaceuticals, Inc.
- Intellia Therapeutics, Inc.
- OxThera
Methodology
LOADING...
